Core Insights - The treatment options for influenza antiviral therapy in children under 5 years old are currently limited in China, with only neuraminidase inhibitors like Oseltamivir approved for this age group [1][2] - There is a significant increase in pediatric emergency visits due to influenza, with hospitals reporting a rise of approximately 20% in emergency cases [1] - The H3N2 strain of influenza poses a greater risk this year compared to last year's H1N1, leading to increased concerns about severe complications in children [1] Group 1: Current Treatment Landscape - The only approved antiviral treatment for children under 5 is Oseltamivir, which has some adverse effects such as nausea and vomiting, and requires a 5-day regimen [2] - There is a rising trend in resistance rates according to national influenza monitoring data, indicating a substantial unmet need for effective antiviral treatments for young children [2] Group 2: Research and Development - A clinical study led by a team from Beijing Children's Hospital is evaluating the safety and efficacy of Marbofloxacin suspension in children aged 1 to under 5, which could expand treatment options for this demographic [2] - Marbofloxacin is the first innovative antiviral RNA polymerase inhibitor approved in China in the last 20 years, but it is currently only approved for those aged 5 and older [2] - The market for pediatric influenza antiviral drugs is expanding, with domestic companies like Senju Pharmaceutical and Qifeng Kairui developing new treatments aimed at younger patients [3]

Core Viewpoint - There is a significant increase in pediatric emergency visits due to influenza, particularly among children under 5 years old, highlighting the urgent need for effective antiviral treatments for this demographic [1][2]. Group 1: Pediatric Influenza Situation - Recent data from multiple hospitals in Shanghai indicates a notable rise in pediatric emergency visits, primarily due to influenza cases, with a reported 20% increase in emergency visits at Shanghai Jiao Tong University Affiliated Xinhua Hospital [1]. - The H3N2 strain of influenza is particularly concerning this year, as it has a faster mutation rate and higher transmissibility compared to last year's H1N1 strain, leading to increased risks of severe respiratory complications in children [1]. - Children under 5 years old represent a high-risk group for severe influenza complications, with a reported incidence rate that is over three times higher than that of the 15 to 59 age group [1]. Group 2: Antiviral Treatment Landscape - Current antiviral treatment options for influenza in children under 5 years are limited, with only neuraminidase inhibitors like Oseltamivir approved for use, which can cause side effects such as nausea and vomiting [1]. - There is a rising trend in antiviral resistance, indicating a significant unmet need for effective antiviral treatments for young children [1]. - Recent clinical research led by a team from Capital Medical University has evaluated the safety and efficacy of Marbofloxacin suspension for influenza in children aged 1 to under 5 years, potentially expanding treatment options for this age group [2]. - The market for pediatric influenza antiviral medications is expanding, with new products like the RNA polymerase inhibitor, Madurosavir, being developed specifically for children aged 2 to 11 years [2].

Core Viewpoint - The flu season of 2025 is reported to be more severe than in the past three years, with increased cases of flu-like illnesses (ILI) across both northern and southern regions of China, leading to a shortage of specific flu medications, particularly for children [1][3][11]. Summary by Sections Flu Season Severity - The latest report from the Chinese Center for Disease Control and Prevention indicates that from November 10 to 16, 2025, the ILI percentage in southern provinces was 6.7% and in northern provinces was 7.0%, both higher than the previous week and the same period in 2022, 2023, and 2024 [3][11]. Medication Shortages - Many pharmacies are experiencing shortages of flu medications, particularly the children's version of the antiviral drug "速福达" (Mabalaoshuwei). Traditional antiviral drugs like Oseltamivir are still available but are also in high demand [3][9][11]. - A pharmacy reported that Oseltamivir has been out of stock for over two weeks, with expectations for new supplies to arrive soon, while "速福达" is not expected to be restocked [9][11]. Hospital Preference - Parents prefer hospitals for flu treatment over pharmacies, as they trust clinical doctors more. The original manufacturers of "速福达" and Oseltamivir are ensuring a broad supply to hospitals across the country [10][11]. - Clinical demand for children's flu medications is increasing, with doctors noting that while there are no supply issues for Oseltamivir and Mabalaoshuwei, delivery disruptions can occur due to high demand [11][12]. Drug Efficacy and Usage - Oseltamivir is suitable for children aged 1 year and older, while Mabalaoshuwei is effective for children aged 5 to 12, with the latter being a single-dose oral medication, making it more convenient for parents [11][13]. - The latest guidelines indicate that flu medications are essential for treatment, as common cold medications do not replace antiviral drugs [12][13]. Market Dynamics - The market for children's single-dose flu medications is expected to become more competitive as several domestic pharmaceutical companies are developing similar products, which may challenge the current dominance of "速福达" [16][17]. - Recent approvals for new antiviral drugs targeting children are underway, with a focus on single-dose formulations, which could expand treatment options for pediatric patients [16][17].

Core Insights - Roche Pharmaceuticals China launched the innovative flu drug, Baloxavir Marboxil (速福达), at the 8th China International Import Expo, highlighting its latest clinical data on family transmission prevention and cross-border health protection solutions [1][10] Group 1: Flu Prevention and Treatment Ecosystem - Roche China collaborates with the China Population Welfare Foundation, medical experts, and digital platform partners to create a comprehensive flu prevention and treatment ecosystem covering prevention, detection, treatment, and assurance [4] - The global flu season, from October to March, sees 3 to 5 million severe cases and 290,000 to 650,000 deaths annually, with increased cross-border movement heightening flu transmission risks [6] Group 2: Vaccination and Public Awareness - In China, the flu vaccination rate remains low at 3.84% for the 2022-2023 season, significantly lower than in Europe and the U.S., indicating a need for improved public awareness and vaccination efforts [8] - The China Population Welfare Foundation initiated a global travel protection campaign for the flu season, aiming to enhance public understanding of flu prevention [6] Group 3: Baloxavir Marboxil Efficacy - Clinical data shows that the family treatment regimen of Baloxavir Marboxil can reduce household flu infection rates from 54.45% to 6.93% and shorten symptom duration from 1.14 days to 0.11 days [10] - The drug's single-dose oral administration improves adherence compared to multi-day regimens, addressing challenges in pediatric medication where 43% of children face difficulties [10][11] Group 4: Pediatric Considerations - Children are particularly vulnerable to flu, with longer illness duration and higher viral shedding, necessitating specialized formulations for effective treatment [10] - The Baloxavir Marboxil pediatric formulation is designed for ease of use, allowing precise dosing based on weight, thus enhancing the medication experience for children [11] Group 5: Commitment to Public Health - Roche emphasizes its commitment to public health and the "Healthy China 2030" initiative, aiming to enhance flu prevention and treatment through scientific advancements and collaboration with various sectors [11]